TipRanks
Go Ultimate55% OFF

Poxel SA (PXXLF) AI Stock Analysis

PXXLF

Poxel SA

(Other OTC:PXXLF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Commercial partnership with Sumitomo PharmaA revenue-generating, arm’s-length commercialization partnership in Japan provides durable non-dilutive cash via milestones/royalties and shifts commercialization burden to an established local partner. This reduces short-term capex needs and supports predictable collaboration receipts over coming quarters.
Negative Factors
Highly stressed balance sheetDeep negative equity combined with rising debt materially limits financial flexibility, increasing refinancing and dilution risk. Over a multi‑month horizon this constrains runway for R&D and commercialization investments and raises the probability management must seek costly external funding.

Poxel SA (PXXLF) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%PXXLF-12.00%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$11.01M
Dividend Yield
―
Average Volume (3M)
718
Price to Earnings (P/E)
-0.4
Beta (1Y)
-0.13
Revenue Growth
―
EPS Growth
―
Country
US
Employees
5
Sector
General
Sector Strength
55
Industry
Biotechnology

Poxel SA Business Overview & Revenue Model

Company Description

Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Imeglimin, is a...

Poxel SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

PXXLF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
FR:MEDCLFR:MEDCL50NeutralEUR 948.13M-28.97――-23.21%-50.69%
FR:IVAFR:IVA46NeutralEUR 760.35M-6.00-1625.48%―-99.64%68.67%
FR:GNFTFR:GNFT44NeutralEUR 541.90M-5.32279.22%―27.70%-162.89%
FR:ALGAEFR:ALGAE43NeutralEUR 46.73M-4.49-32.62%―3.22%24.05%
FR:ALVALFR:ALVAL37UnderperformEUR 22.31M-2.13-87.66%―183.47%57.15%

* General Sector Average

Performance Comparison

0%100%200%300%PXXLFFR:GNFTFR:IVAFR:ALVALFR:ALGAEFR:MEDCLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
PXXLF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PXXLFPoxel SA0.22-0.03-12.00%
FR:GNFTGenfit SA10.867.31205.92%
FR:IVAInventiva SA3.18-0.34-9.66%
FR:ALVALValbiotis SA0.63-0.01-0.95%
FR:ALGAEFermentalg SA0.39-0.09-19.59%
FR:MEDCLMedinCell SA26.36-10.42-28.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.